Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A-Reference-Cited by-同舟云学术

Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A

Published:2000-05 Issue:3 Volume:6 Page:140-149
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

Powell J. S.,Bush M.,Harrison J.,Abildgaard C.,Vosburgh E.,Thompson A. R.,Hurst D.

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2516.2000.00407.x/fullpdf

Reference37 articles.

1. Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee;Kasper;Transfusion,1993

2. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia;Goedert;N Engl J Med,1989

3. Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B;Mannucci;Haemophilia,1995

4. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Haemostasis;Mannucci;Thromb Haemostas,1989

5. Effect of dry-heating of coagulation factor concentrates at 80 °C for 72 hours on transmission of non-A, non-B hepatitis;Study Group of the UK Haemophiliac Centre Directors;Lancet,1988

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgery in a Patient with Haemophilia A and Lymphoma;Case Reports in Hematology;2020-03-19

2. Product type and other environmental risk factors for inhibitor development in severe hemophilia A;Research and Practice in Thrombosis and Haemostasis;2018-04

3. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A;Expert Opinion on Drug Metabolism & Toxicology;2016-08-19

4. Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins;Journal of Pharmaceutical Sciences;2013-07

5. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies;Haemophilia;2012-02-15